Cargando…
The association between tumor mutational burden and prognosis is dependent on treatment context
In multiple cancer types, high tumor mutational burden (TMB) is associated with longer survival after treatment with immune checkpoint inhibitors (ICI). The association of TMB with survival outside of the immunotherapy context is poorly understood. We analyzed 10,233 patients (80% non-ICI-treated, 2...
Autores principales: | Valero, Cristina, Lee, Mark, Hoen, Douglas, Wang, Jingming, Nadeem, Zaineb, Patel, Neal, Postow, Michael A., Shoushtari, Alexander N., Plitas, George, Balachandran, Vinod P., Smith, J. Joshua, Crago, Aimee M., Roche, Kara C. Long, Kelly, Daniel W., Samstein, Robert M., Rana, Satshil, Ganly, Ian, Wong, Richard J., Hakimi, A. Ari, Berger, Michael F., Zehir, Ahmet, Solit, David B., Ladanyi, Marc, Riaz, Nadeem, Chan, Timothy A., Seshan, Venkatraman E., Morris, Luc G.T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796993/ https://www.ncbi.nlm.nih.gov/pubmed/33398197 http://dx.doi.org/10.1038/s41588-020-00752-4 |
Ejemplares similares
-
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021) -
The DNA damage response in immunotherapy and radiation
por: Samstein, Robert M., et al.
Publicado: (2018) -
Mitochondrial DNA copy number variation across human cancers
por: Reznik, Ed, et al.
Publicado: (2016) -
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
por: Yang, Wei, et al.
Publicado: (2019) -
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
por: Morris, Luc G.T., et al.
Publicado: (2016)